Imatinib mesylate inhibits tumorigenicity of malignant fibrous histiocytoma cells in vivo

Anticancer Research

Volumn 27, Issue 1 A, 2007, Pages 423-430

  Irsan, Istan ^a   Akisue, Toshihiro ^a   Hara, Hitomi ^a   Fujimoto, Takuya ^a   Imabori, Masaya ^a   Doita, Minoru ^a   Kuroda, Ryosuke ^a   Fujioka, Hiroyuki ^a   Kawamoto, Teruya ^b   Yamamoto, Tetsuji ^b   Kurosaka, Masahiro ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KAGAWA UNIVERSITY   (Japan)

Author keywords

c Kit; Imatinib mesylate; MFH; Nude mice; PDGFRs; Tumorigenicity

Indexed keywords

IMATINIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; STEM CELL FACTOR RECEPTOR;

AMINO ACID SEQUENCE; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CARCINOGENICITY; CELL PROLIFERATION; CONTROLLED STUDY; DERMATOFIBROMA; DRUG INHIBITION; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; HISTIOCYTOMA, MALIGNANT FIBROUS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, NUDE; PHOSPHORYLATION; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; RNA, MESSENGER; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33847650135     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Ozzello L, Stout AP and Murray MR: Cultural characteristics of malignant histiocytomas and fibrous xanthomas. Cancer 16: 331-344, 1963.
2. Gazziola C, Cordani N, Wasserman B, Carta S, Colombatti A and Perris R: Malignant fibrous histiocytoma: a proposed cellular origin and identification of its characterizing gene transcripts. Int J Oncol 23: 343-351, 2003.
3. Borden EC, Baker LH, Bell RS, Bramwell V, Demetri GD, Eisenberg BL, Fletcher CDM, Fletcher JA, Ladanyi M, Meltzer P, O'Sullivan B, Parkinson DR, Pisters PWT, Saxman S, Singer S, Sundaram M, van Oosterom AT, Verweif J, Waalen J, Weiss SW and Brennan MF: Soft tissue sarcoma of adults: state of the translational science. Clin Cancer Res 9: 1941-1956, 2003.
4. Cormier JN and Pollock RE: Soft tissue sarcoma. CA Cancer J Clin 54: 94-109, 2004.
5. Spira AI and Ettinger DS: The use of chemotherapy in soft tissue sarcomas. Oncologist 7: 348-359, 2002.
6. Heldin CH and Westermark B: Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 79: 1283-1316, 1999.
7. Lennartsson J, Voytyuk O, Heiss E, Sundberg C, Sun J and Ronnstrand L: C-Kit signal transduction and involvement in cancer. Cancer Ther 3: 5-28, 2005.
8. Ashman LK: The biology of stem cell factor and its receptor C-kit. Int J Biochem Cell Biol 31: 1037-1051, 1999.
9. Basciani S, Mariani S, Arizzi M, Ulisse S, Rucci N, Jannini EA, Della Rocca C, Manicone A, Carani C, Spera G and Gnessi L: Expression of platelet-derived growth factor-A (PDGF-A), PDGF-B, PDGF receptor-α and -β during human testicular development and disease. J Clin Endocrinol Metab 87: 2310-2319, 2002.
10. Kawamoto T, Akisue T, Marui T, Nakatani T, Hitora T, Fujita I, Kurosaka M and Yamamoto T: Inhibitory effect of STI571 on cell proliferation of human malignant fibrous histiocytoma cell lines. Anticancer Res 24: 2675-2680, 2004.
11. Abdiu A, Walz TM, Nishikawa BK, Wingren S, Larsson SE and Wasteson A: Human malignant fibrous histicytoma in vitro: growth characteristics and their association with expression of mRNA for platelet-derived growth factor, tranforming growth factor-alpha and their receptors. Eur J Cancer 34: 2094-2100, 1998.
12. Krystal GW, Honsawek S, Litz J and Buchdunger E: The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin Cancer Res 6: 3319-3326, 2000.
13. Sjoblom T, Shimizu A, O'Brien KP, Pietras K, Dai Cin P, Buchdunger E, Dumanski JP, Ostman A and Heldin CH: Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor anatagonist STI571 through induction of apoptosis. Cancer Res 61: 5778-5783, 2001.
14. Bauer S, Corless CL, Heinrich MC, Dirsch O, Antoch G, Kanja J, Seeber S and Schutte J: Respone to imatinib mesylate of a gastrointestinal stromal tumor with very low expression of KIT. Cancer Chemother Pharmacol 57: 261-265, 2003.
15. McGary EC, Weber K, Mills L, Doucet M, Lewis V, Lev DC, Fidler IJ and Bar-Eli M: Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571. Clin Cancer Res 8: 3584-3591, 2002.
16. Tayal S, Classen E, Bemis L and Robinson WA: c-kit expression in de-differentiated and well-differentiated liposarcoma; immunohistochemistry and genetic analysis. Anticancer Res 25: 2215-2220, 2005.
17. Vitali R, Cesi V, Nicotra MR, McDowell HP, Donfrancesco A, Mannarino O, Natali PG, Raschella G and Dominici C: c-Kit is preferentially expressed in MYCN-amplified neuroblastoma and its effect on cell proliferation is inhibited in vitro by STI571. Int J Cancer 106: 147-152, 2003.
18. Matei D, Chang DD and Jeng MH: Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor α and Akt inactivation. Clin Cancer Res 10: 681-690, 2004.
19. Basciani S, Brama M, Mariani S, De Luca G, Arizzi M, Vesci L, Pisano C, Dolci S, Spera G and Gnessi L: Imatinib mesylate inhibits Leydig cell tumor growth: evidence for in vitro and in vivo activity. Cancer Res 65: 1897-1903, 2005.
20. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ and Lydon NB: Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295: 139-145, 2000.
21. Mauro MJ, O'Dwyer M, Heinrich MC and Druker BJ: STI571: a paradigm of new agents for cancer therapeutics. J Clin Oncol 20: 325-334, 2002.
22. Rubin BP, Schuetze SM, Eary JF, Norwood TH, Mirza S, Conrad EU and Bruckner JD: Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J Clin Oncol 20: 3586-3591, 2002.
23. Uehara H, Kim SJ, Karashima T, Shepherd DL, Fan D, Tsan R, Killion JJ Logothetis C, Mathew P and Fidler IJ: Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases. J Natl Cancer Inst 95: 458-470, 2003.
24. Ochel HJ, Gademann G, Rocken C and Wordehoff H: Effects of imatinib mesylate on adenoid cystic carcinomas. Anticancer Res 25: 3659-3664, 2005.
25. 18fluoro-deoxyglucose-positron emission tomography. Anticancer Res 25: 4591-4594, 2005.
26. Nakatani T, Marui T, Yamamoto T, Hitora T, Akisue T, Kawamoto T, Nagira K, Fujita I, Matsumoto K, Yoshiya S and Kurosaka M: Expression of stem cell factor and c-kit in human malignant fibrous histiocytoma cell line (TNMY1). Anticancer Res 23: 2329-2333, 2003.
27. Taniuchi K, Yamada Y, Nonomura A and Takehara K: Immunohistochemical analysis of platelet-derived growth factor and its receptors in fibrohistiocytic tumors. J Cutan Pathol 24: 393-397, 1997.
28. Manley PW, Cowan-Jacob SW, Buchdunger E, Fabbro D, Fendrich G, Furet P, Meyer T and Zimmermann J: Imatinib: a selective tyrosine kinase inhibitor. Eur J Cancer 38: S19-S27, 2002.
29. Wolff NC, Randle DE, Egorin MJ, Minna JD and Ilaria RL Jr: Imatinib mesylate efficiently achieves theurapetic intratumor concentrations in vivo but has limited activity in a xenograft model of small cell lung cancer. Clin Cancer Res 10: 3528-3534, 2004.
30. Peng B, Hayes M, Resta D, Racine-Poon A, Druker BJ, Talpaz M, Sawyers CL, Rosamilia M, Ford J, Lloyd P and Capdeville R: Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol 22: 935-942, 2004.